Actively Recruiting
Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients
Led by European Institute of Oncology · Updated on 2024-05-06
20
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The 2017 World Health Organization (WHO) introduced a new category of high-grade, well-differentiated neuroendocrine neoplasms (NENs) that called neuroendocrine tumors (NETs) G3 in pancreatic NENs classification and, then, in 2019, for all gastro-entero-pancreatic (GEP) tract NENs. The new classification made it possible to separate NETs G3 from high-grade, poorly-differentiated, NENs that are called neuroendocrine carcinomas (NECs). However, in clinical practice, we observed that several clinical, pathological and radiological differences are arising among NET G3 patients, suggesting that a multiparametric definition of NET G3 is needed.
CONDITIONS
Official Title
Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histological diagnosis of well-differentiated neuroendocrine tumor G3 reviewed by a NEN-dedicated pathologist
- Age over 18 years
- Signed written informed consent
- Available tumor tissue (formalin-fixed paraffin-embedded, FFPE) preferably within 6 months; if unavailable, willing to undergo a new biopsy
- For late-NET G3 patients, previous 68 Gallium-DOTATOC PET/CT and 18 fluorodeoxyglucose (FDG)-PET/CT from NET G1/2 diagnosis available for specialist review
You will not qualify if you...
- Diagnosis of well-differentiated NET G1/2 or poorly-differentiated neuroendocrine carcinoma (NEC)
- Diagnosis of mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) with NET G3 component
- Cytological diagnosis of NET G3 without available tumor tissue for analysis
- Concurrent neoplastic diseases such as advanced breast or prostate cancer under hormonal treatment, or hematologic diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
European Institute of Oncology
Milan, Italy, 20141
Actively Recruiting
Research Team
F
Francesca Spada, MD
CONTACT
C
Cristina Mazzon
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here